1
|
Opacic D, Klüß C, Becker T, Rudloff M, Lauenroth V, Deutsch M, Costard-Jäckle A, Fox H, Schramm R, Morshuis M, Gummert J, Rojas S. Comparison of Different Temporary RVAD Systems in Patients Undergoing LVAD Implantation. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.1081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
2
|
Kalsi RS, Ostrowska A, Olson A, Quader M, Deutsch M, Arbujas-Silva NJ, Symmonds J, Soto-Gutierrez A, Crowley JJ, Reyes-Mugica M, Sanchez-Guerrero G, Jaeschke H, Amiot BP, Cascalho M, Nyberg SL, Platt JL, Tafaleng EN, Fox IJ. A non-human primate model of acute liver failure suitable for testing liver support systems. Front Med (Lausanne) 2022; 9:964448. [PMID: 36250086 PMCID: PMC9561471 DOI: 10.3389/fmed.2022.964448] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2022] [Accepted: 09/12/2022] [Indexed: 01/26/2023] Open
Abstract
Acute hepatic failure is associated with high morbidity and mortality for which the only definitive therapy is liver transplantation. Some fraction of those who undergo emergency transplantation have been shown to recover native liver function when transplanted with an auxiliary hepatic graft that leaves part of the native liver intact. Thus, transplantation could have been averted with the development and use of some form of hepatic support. The costs of developing and testing liver support systems could be dramatically reduced by the availability of a reliable large animal model of hepatic failure with a large therapeutic window that allows the assessment of efficacy and timing of intervention. Non-lethal forms of hepatic injury were examined in combination with liver-directed radiation in non-human primates (NHPs) to develop a model of acute hepatic failure that mimics the human condition. Porcine hepatocyte transplantation was then tested as a potential therapy for acute hepatic failure. After liver-directed radiation therapy, delivery of a non-lethal hepatic ischemia-reperfusion injury reliably and rapidly generated liver failure providing conditions that can enable pre-clinical testing of liver support or replacement therapies. Unfortunately, in preliminary studies, low hepatocyte engraftment and over-immune suppression interfered with the ability to assess the efficacy of transplanted porcine hepatocytes in the model. A model of acute liver failure in NHPs was created that recapitulates the pathophysiology and pathology of the clinical condition, does so with reasonably predictable kinetics, and results in 100% mortality. The model allowed preliminary testing of xenogeneic hepatocyte transplantation as a potential therapy.
Collapse
Affiliation(s)
- Ranjeet S. Kalsi
- Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
| | - Alina Ostrowska
- Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States,Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States,Pittsburgh Liver Research Center, University of Pittsburgh, Pittsburgh, PA, United States
| | - Adam Olson
- Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
| | - Mubina Quader
- Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
| | - Melvin Deutsch
- Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
| | - Norma J. Arbujas-Silva
- Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
| | - Jen Symmonds
- Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
| | - Alejandro Soto-Gutierrez
- Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States,Pittsburgh Liver Research Center, University of Pittsburgh, Pittsburgh, PA, United States,McGowan Institute for Regenerative Medicine, Pittsburgh, PA, United States
| | - John J. Crowley
- Division of Vascular and Interventional Radiology, Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, United States
| | - Miguel Reyes-Mugica
- Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States,Department of Pathology, Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, United States
| | - Giselle Sanchez-Guerrero
- Department of Pharmacology, Toxicology and Therapeutics, The University of Kansas Medical Center, Kansas City, KS, United States
| | - Hartmut Jaeschke
- Department of Pharmacology, Toxicology and Therapeutics, The University of Kansas Medical Center, Kansas City, KS, United States
| | - Bruce P. Amiot
- Department of Surgery, Mayo Clinic, Rochester, MN, United States
| | - Marilia Cascalho
- Departments of Surgery and Microbiology and Immunology, University of Michigan, Ann Arbor, MI, United States
| | - Scott L. Nyberg
- Department of Surgery, Mayo Clinic, Rochester, MN, United States
| | - Jeffrey L. Platt
- Departments of Surgery and Microbiology and Immunology, University of Michigan, Ann Arbor, MI, United States
| | - Edgar N. Tafaleng
- Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States,Edgar N. Tafaleng,
| | - Ira J. Fox
- Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States,Pittsburgh Liver Research Center, University of Pittsburgh, Pittsburgh, PA, United States,McGowan Institute for Regenerative Medicine, Pittsburgh, PA, United States,*Correspondence: Ira J. Fox,
| |
Collapse
|
3
|
Tailleur E, Wenger E, Deutsch M, Romanini M, Aguilà-Avilés D. Structural investigations of a magnetoelectric plastic crystal by complementary in situ multi-constraint ( T, P, E) SC-XRD experiments. Acta Cryst Sect A 2022. [DOI: 10.1107/s2053273322094955] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/19/2023]
|
4
|
Pillet S, Deutsch M, Yangui A, Pages O, Baker Shoker M, Bouchez G, Boukheddaden K. Pressure-induced phase transition in the ferroelectric hybrid perovskite (C 6H 11NH 3) 2[PbBr 4]. Acta Cryst Sect A 2022. [DOI: 10.1107/s2053273322095936] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/19/2023]
|
5
|
George TJ, Yothers G, Jacobs SA, Finley GG, Wade JL, Rocha Lima CMSP, Rose JS, Pahuja S, Krishnamurthy A, Krauss JC, Deutsch M, Fabregas JC, Lee JJ, Allegra CJ, Wolmark N. Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.4_suppl.099] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
99 Background: Although immunotherapy shows no benefit in microsatellite stable (MSS) colorectal cancer, preclinical models suggest that radiotherapy (RT) can enhance neoantigen presentation, modulate the microenvironment, and improve the likelihood of anti-tumor activity with checkpoint inhibitor use. Using a “window-of-opportunity” study design, this prospective phase II trial will determine the safety and activity of this approach with the anti-PD-L1 agent durvalumab (MEDI4736). Methods: Stage II/III patients (pts) with MSS rectal cancer undergoing standard NCCN guideline-compliant neoadjuvant chemoradiotherapy (CRT) followed by definitive surgery were eligible. Treatment included durvalumab (750mg IV infusion once every 2 wks) for 4 total doses beginning within 3-7 days after CRT completion followed by surgery within 8-12 wks of the final CRT dose. Primary end point (EP): Improvement in modified neoadjuvant rectal cancer (mNAR) score (goal 10.6) compared to historical controls (15.6) targeting a 20% DFS RR reduction and 3-4% absolute OS improvement. Secondary EPs: toxicity, pCR, cCR, therapy completion, negative surgical margins, sphincter preservation, and exploratory assessments of tumor-infiltrating lymphocytes, tumor Immunoscore, circulating immunologic profiles, and molecular predictors of response. We test H0: mNAR ≥15.6 vs HA: mNAR <15.6 at alpha 0.10 one-sided with statistical significance defined as p<0.1. Results: From May 2018 to October 2020, 45 pts were enrolled with 40 pts evaluable for mNAR. Mean mNAR was 12.03 (80% CI: 9.29-14.97) (p=0.06 one-sided). pCR=22.2%; cCR=31.1%; R0 resection=81.0%, and sphincter preservation=71.4%. Side effects were consistent with both CRT and durvalumab safety profile. Most common grade 3 AEs included diarrhea, lymphopenia, and back pain. There was one grade 4 AE (elevated amylase/lipase) and no grade 5 AEs. Remaining secondary and correlative immunologic end points are still being assessed. Conclusions: Durvalumab immediately following CRT prior to surgery for definitive management of rectal cancer was safe and without unexpected short-term toxicities. The primary end point of mean mNAR score was significantly less than our historical control, warranting further investigation. Correlative analyses for immunologic markers of response including PD-(L)1 expression and Immunoscore are ongoing. NCT 03102047. Support: AstraZeneca-Medimmune, NSABP Foundation. Clinical trial information: NCT03102047.
Collapse
Affiliation(s)
- Thomas J. George
- NSABP Foundation, and The University of Florida Health Cancer Center, Gainesville, FL
| | - Greg Yothers
- NRG Oncology, and The University of Pittsburgh, Pittsburgh, PA
| | | | - Gene Grant Finley
- NSABP Foundation, and Allegheny Health Network Cancer Institute, Pittsburgh, PA
| | - James Lloyd Wade
- NSABP Foundation, and Decatur Memorial Hospital/NCORP, Decatur, IL
| | | | | | - Shalu Pahuja
- NSABP Foundation, and West Virginia University Hospital, Morgantown, WV
| | - Anuradha Krishnamurthy
- NSABP Foundation, Inc., and UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA
| | - John C. Krauss
- NSABP Foundation Inc., and University of Michigan, Ann Arbor, MI
| | - Melvin Deutsch
- NSABP Foundation Inc., and The University of Pittsburgh Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA
| | | | - James J. Lee
- NSABP Foundation, and UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - Carmen Joseph Allegra
- NRG Oncology, and The University of Florida/UF Health Cancer Center, Gainesville, FL
| | - Norman Wolmark
- NRG Oncology, and The University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA
| |
Collapse
|
6
|
Martin N, Bannenberg LJ, Deutsch M, Pappas C, Chaboussant G, Cubitt R, Mirebeau I. Field-induced vortex-like textures as a probe of the critical line in reentrant spin glasses. Sci Rep 2021; 11:20753. [PMID: 34675354 PMCID: PMC8531314 DOI: 10.1038/s41598-021-99860-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2021] [Accepted: 09/29/2021] [Indexed: 11/09/2022] Open
Abstract
We study the evolution of the low-temperature field-induced magnetic defects observed under an applied magnetic field in a series of frustrated amorphous ferromagnets (Fe\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$_{1-x}$$\end{document}1-xMn\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$_{x}$$\end{document}x)\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$_{75}$$\end{document}75P\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$_{16}$$\end{document}16B\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$_{3}$$\end{document}3Al\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$_{3}$$\end{document}3 (“a-Fe\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$_{1-x}$$\end{document}1-xMn\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$_{x}$$\end{document}x”). Combining small-angle neutron scattering and Monte Carlo simulations, we show that the morphology of these defects resemble that of quasi-bidimensional spin vortices. They are observed in the so-called “reentrant” spin-glass (RSG) phase, up to the critical concentration \documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$x_{\mathrm{C}} \approx 0.36$$\end{document}xC≈0.36 which separates the RSG and “true” spin glass (SG) within the low temperature part of the magnetic phase diagram of a-Fe1−xMnx. These textures systematically decrease in size with increasing magnetic field or decreasing the average exchange interaction, and they finally disappear in the SG sample (\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$x = 0.41$$\end{document}x=0.41), being replaced by field-induced correlations over finite length scales. We argue that the study of these nanoscopic defects could be used to probe the critical line between the RSG and SG phases.
Collapse
Affiliation(s)
- N Martin
- Université Paris-Saclay, CNRS, CEA, Laboratoire Léon Brillouin, 91191, Gif-sur-Yvette, France.
| | - L J Bannenberg
- Faculty of Applied Science, Delft University of Technology, 2629 JB, Delft, The Netherlands
| | - M Deutsch
- CNRS, CRM2, Université de Lorraine, Nancy, France
| | - C Pappas
- Faculty of Applied Science, Delft University of Technology, 2629 JB, Delft, The Netherlands
| | - G Chaboussant
- Université Paris-Saclay, CNRS, CEA, Laboratoire Léon Brillouin, 91191, Gif-sur-Yvette, France
| | - R Cubitt
- Institut Laue Langevin, BP156, 38042, Grenoble, France
| | - I Mirebeau
- Université Paris-Saclay, CNRS, CEA, Laboratoire Léon Brillouin, 91191, Gif-sur-Yvette, France
| |
Collapse
|
7
|
Deutsch M, Wirsing S, Kaiser D, Fink RF, Tegeder P, Engels B. Geometry relaxation-mediated localization and delocalization of excitons in organic semiconductors: A quantum chemical study. J Chem Phys 2020; 153:224104. [DOI: 10.1063/5.0028943] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Affiliation(s)
- M. Deutsch
- Institut für Physikalische und Theoretische Chemie, Universität Würzburg,, Emil-Fischer-Str. 42, D-97074 Würzburg, Germany
| | - S. Wirsing
- Institut für Physikalische und Theoretische Chemie, Universität Würzburg,, Emil-Fischer-Str. 42, D-97074 Würzburg, Germany
| | - D. Kaiser
- Institut für Physikalische und Theoretische Chemie, Universität Würzburg,, Emil-Fischer-Str. 42, D-97074 Würzburg, Germany
| | - R. F. Fink
- Institut für Physikalische und Theoretische Chemie, Universität Tübingen, Auf der Morgenstelle 18, 72076 Tübingen, Germany
| | - P. Tegeder
- Physikalisch-Chemisches Institut, Universität Heidelberg, Im Neuenheimer Feld 253, 69120 Heidelberg, Germany
| | - B. Engels
- Institut für Physikalische und Theoretische Chemie, Universität Würzburg,, Emil-Fischer-Str. 42, D-97074 Würzburg, Germany
| |
Collapse
|
8
|
George TJ, Yothers G, Jacobs SA, Finley GG, Parekh HD, Moore TD, Maalouf BN, Krauss JC, Deutsch M, Lee JJ, Allegra CJ, Wolmark N. NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.4_suppl.tps264] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
TPS264 Background: Clinical improvements for locally advanced rectal cancer have been relatively static over the past few decades. While immunotherapy shows no benefit in microsatellite stable (MSS) colorectal cancer, preclinical models suggest that radiotherapy (RT) can enhance neoantigen presentation, modulate the microenvironment, and improve the likelihood of anti-tumor activity with checkpoint inhibitor use. Using a “window-of-opportunity” study design, this prospective phase II trial will determine the safety and activity of this approach with the anti-PD-L1 agent durvalumab (MEDI4736). Methods: This multi-center phase II trial is currently enrolling patients (pts) with rectal cancer who are undergoing standard NCCN guideline-compliant neoadjuvant chemoradiotherapy (CRT). Eligibility includes pts with MSS stage II-IV rectal cancer with adequate organ function and pre-treatment diagnostic tumor available for profiling with intent to proceed to surgical resection after CRT. Stage IV disease must be limited such that the primary pelvic tumor requires definitive management. Standard ineligibility criteria include active infections, systemic steroid use, or other conditions making immunotherapy use unsafe. Treatment includes durvalumab (750mg IV infusion once every 2 wks) for 4 total doses beginning within 3-7 days after CRT completion. Surgery must be within 8-12 wks of the final CRT dose. Primary endpoint is a demonstrated improvement in Neoadjuvant Rectal Cancer (NAR) score compared to historical controls targeting a 20% relative risk reduction in DFS and 3-4% absolute OS improvement. Secondary endpoints include OS, DFS, toxicity, pCR, cCR, therapy completion, negative surgical margins, sphincter preservation, off-target “abscopal” effects for the subset of stage IV pts, and exploratory assessments of tumor infiltrating lymphocytes, tumor Immunoscore, circulating immunologic profiles, and molecular predictors of response. A safety run-in phase has completed as a precedent to full enrollment. Enrollment now continues to 47 total pts to achieve 41 surgically evaluable pts. Support: AstraZeneca-Medimmune, NSABP Foundation. Clinical trial information: NCT03102047.
Collapse
Affiliation(s)
- Thomas J. George
- NSABP Foundation, Inc., and The University of Florida Health Cancer Center, Gainesville, FL
| | | | - Samuel A. Jacobs
- NSABP Foundation, Inc., and The University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | | | | | | | - Bassam Nabih Maalouf
- NSABP Foundation, Inc., and Cancer Care Specialists of Illinois/Crossroads Cancer Center, Effingham, IL
| | - John C. Krauss
- NSABP Foundation Inc., and University of Michigan, Ann Arbor, MI
| | - Melvin Deutsch
- NSABP Foundation Inc., and University of Pittsburgh Medical Center, Pittsburgh, PA
| | - James J. Lee
- NSABP Foundation Inc., and University of Pittsburgh Medical Center, Pittsburgh, PA
| | | | - Norman Wolmark
- NSABP Foundation, Inc., and The University of Pittsburgh, Pittsburgh, PA
| |
Collapse
|
9
|
Georgiou A, Papatheodoridis G, Deutsch M, Alexopoulou A, Vlachogiannakos J, Ioannidou P, Papageorgiou MV, Voulgaris T, Papadopoulos N, Tsibouris P, Papavdi M, Poulia KA, Kontogianni M. SUN-PO067: Prevalence of Malnutrition by GLIM Criteria and of Sarcopenia by the New Definition and Their Associations with 1-Year Survival in Cirrhotic Patients. Clin Nutr 2019. [DOI: 10.1016/s0261-5614(19)32701-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
10
|
George TJ, Yothers G, Lee JJ, Deutsch M, Jacobs SA, Allegra CJ, Wolmark N. Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer: NSABP FR-2. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.tps3620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
TPS3620 Background: Locally advanced rectal cancer remains a clinical challenge with few improvements noted over the past few decades. Although immunotherapy has no current clinical role in microsatellite stable (MSS) colorectal cancer, preclinical models suggest that radiotherapy (RT) can enhance neoantigen presentation, modulate the microenvironment, and improve the likelihood of anti-tumor activity with checkpoint inhibitor use. This prospective phase II trial will test that hypothesis in addition to confirming the safety of this approach using a “window-of-opportunity” study design with the anti-PD-L1 agent durvalumab (MEDI4736). Methods: This multi-center phase II trial is currently enrolling patients (pts) with rectal cancer who are undergoing standard NCCN guideline-compliant neoadjuvant chemoradiotherapy (CRT). Eligibility includes pts with MSS stage II-IV rectal cancer with adequate organ function and pre-treatment diagnostic tumor available for profiling who are undergoing CRT with intent to proceed to surgical resection. Stage IV disease must be limited such that the primary pelvic tumor requires definitive management. Standard ineligibility criteria include active infections, systemic steroid use, or other conditions making immunotherapy use unsafe. Treatment includes durvalumab (750mg IV infusion once every 2 wks) for 4 total doses beginning within 3-7 days after CRT completion. Surgery must be within 8-12 wks of the final CRT dose. Primary endpoint is a demonstrated improvement in Neoadjuvant Rectal Cancer (NAR) score compared to historical controls targeting a 20% relative risk reduction in DFS and 3-4% absolute OS improvement. Secondary endpoints include OS, DFS, toxicity, pCR, cCR, therapy completion, negative surgical margins, sphincter preservation, off-target “abscopal” effects for the subset of stage IV pts, and exploratory assessments of tumor infiltrating lymphocytes, circulating immunologic profiles, and molecular predictors of response. A safety run-in phase has completed as a precedent to full enrollment. Enrollment now continues to 47 total pts to achieve 41 surgically evaluable pts. Support: AstraZeneca-Medimmune, NSABP Foundation. Clinical trial information: NCT03102047.
Collapse
Affiliation(s)
- Thomas J. George
- NRG Oncology, and The University of Florida Health Cancer Center, Gainesville, FL
| | - Greg Yothers
- NRG Oncology, and The University of Pittsburgh, Pittsburgh, PA
| | - James J. Lee
- NRG Oncology, and UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - Melvin Deutsch
- NRG Oncology, and UPMC Dpt Radiation Oncology, Pittsburgh, PA
| | - Samuel A. Jacobs
- NRG Oncology,and The University of Pittsburgh Cancer Institute, Pittsburgh, PA
| | | | - Norman Wolmark
- NRG Oncology, and The Allegheny Health Network Cancer Institute, Pittsburgh, PA
| |
Collapse
|
11
|
George TJ, Yothers G, Lee JJ, Jacobs SA, Deutsch M, Allegra CJ, Wolmark N. NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.4_suppl.tps727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
TPS727 Background: Locally advanced rectal cancer remains a clinical challenge with few improvements noted over the past few decades. Although immunotherapy has no current clinical role in microsatellite stable (MSS) colorectal cancer, preclinical models suggest that radiotherapy (RT) can enhance neoantigen presentation, modulate the microenvironment, and improve the likelihood of anti-tumor activity with checkpoint inhibitor use. This prospective phase II trial will test that hypothesis in addition to confirming safety of this approach using a “window-of-opportunity” study design with the anti-PD-L1 agent durvalumab (MEDI4736). Methods: This multi-center phase II trial is currently enrolling patients (pts) with rectal cancer who are undergoing standard NCCN guideline-compliant neoadjuvant chemoradiotherapy (CRT). Eligibility includes pts with MSS stage II-IV rectal cancer with adequate organ function and pre-treatment diagnostic tumor available for profiling who are undergoing CRT with intentions to proceed to surgical resection. Stage IV disease must be limited such that the primary pelvic tumor requires definitive management. Standard ineligibility criteria include active infections, systemic steroid use, or other conditions making immunotherapy use unsafe. Treatment includes durvalumab (750mg IV infusion once every 2 wks) for 4 total doses beginning within 3-7 days after CRT completion. Surgery must be within 8-12 wks of the final CRT dose. Primary endpoint is a demonstrated improvement in Neoadjuvant Rectal Cancer (NAR) score compared to historical controls targeting a 20% relative risk reduction in DFS and 3-4% absolute OS improvement. Secondary endpoints include OS, DFS, toxicity, pCR, cCR, therapy completion, negative surgical margins, sphincter preservation, off-target “abscopal” effects for the subset of stage IV pts, and exploratory assessments of tumor infiltrating lymphocytes, circulating immunologic profiles, and molecular predictors of response. A safety run-in phase has completed as a precedent to full enrollment. Enrollment now continues to 47 total pts to achieve 41 surgically evaluable pts. NCT03102047. Support: AstraZeneca-Medimmune, NSABP Foundation Clinical trial information: NCT03102047.
Collapse
Affiliation(s)
- Thomas J. George
- NSABP Foundation, and The University of Florida, Gainesville, FL
| | - Greg Yothers
- NSABP Foundation, and The University of Pittsburgh, Pittsburgh, PA
| | - James J. Lee
- NRG Oncology, and University of Pittsburgh Medical Center Cancer Pavilion, Pittsburgh, PA
| | - Samuel A. Jacobs
- NSABP Foundation, and The University of Pittsburgh Cancer Institute, Pittsburgh, PA
| | - Melvin Deutsch
- NSABP Foundation, and The University of Pittsburgh Medical Center, Pittsburgh, PA
| | | | - Norman Wolmark
- NSABP Foundation, and The Allegheny Health Network Cancer Institute, Pittsburgh, PA
| |
Collapse
|
12
|
Georgiou A, Papatheodoridis G, Deutsch M, Alexopoulou A, Vlachogiannakos J, Ioannidou P, Papageorgiou MV, Papadopoulos N, Karagiannakis D, Papavdi M, Prapa A, Poulia KA, Kontogianni M. Evaluation of two nutrition screening tools in predicting malnutrition, sarcopenia and one-year survival In cirrhotic patients. Clin Nutr 2018. [DOI: 10.1016/j.clnu.2018.06.1268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
13
|
Georgiou A, Prapa A, Papatheodoridis G, Deutsch M, Alexopoulou A, Vlachogiannakos J, Ioannidou P, Papageorgiou MV, Papadopoulos N, Karagiannakis D, Papavdi M, Poulia KA, Kontogianni M. Prevalence of malnutrition in a sample of cirrhotic patients. Clin Nutr 2018. [DOI: 10.1016/j.clnu.2018.06.1267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
14
|
George TJ, Yothers G, Lee JJ, Jacobs SA, Deutsch M, Allegra CJ, Wolmark N. NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemotherapy (NAC) in stage II-IV rectal cancer. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.tps3624] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Thomas J. George
- NSABP Foundation and The University of Florida Health Cancer Center, Gainesville, FL
| | | | - James J. Lee
- NSABP Foundation, and The University of Pittsburgh, Pittsburgh, PA
| | - Samuel A. Jacobs
- NSABP Foundation, and The University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | - Melvin Deutsch
- NSABP Foundation, and The University of Pittsburgh Medical Center, Pittsburgh, PA
| | | | - Norman Wolmark
- NSABP/NRG Oncology, and The Allegheny Health Network Cancer Institute, Pittsburgh, PA
| |
Collapse
|
15
|
Hasan S, Gigliotti MJ, Deutsch M, Reed SL, Wegner RE. A 58-Year-Old Woman with Left-Sided Weakness and a History of a Pediatric Brain Tumor: A Case Report. Case Rep Oncol 2018; 11:131-137. [PMID: 29681812 PMCID: PMC5903131 DOI: 10.1159/000487430] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2018] [Accepted: 02/05/2018] [Indexed: 01/08/2023] Open
Abstract
Background An uncommon but well-established complication of cranial irradiation is secondary neoplasm. This case presentation documents a radiation-induced malignant glioma 55 years after being diagnosed with “cerebral sarcoma,” now defined as atypical meningioma. This not only represents the longest reported latency period for a patient initially receiving over 30 Gy, but also provides a valuable historical perspective of neuro-oncology. Clinical Presentation A 58-year-old female presenting with progressive left-sided upper and lower extremity weakness with a past medical history significant for “cerebral sarcoma” was diagnosed with glioblastoma multiforme. This patient had previously been treated with resection and adjuvant radiation therapy via a 280-kVP orthovoltage machine and received 3,390 rad to the posterior three-quarters of the skull for “cerebral sarcoma.” Conclusion A comprehensive investigation of the past medical history helped uncover a mysterious pediatric diagnosis, helped drive the management 5 decades later, and serves as a reminder that seemingly safe interventions may still cause harm.
Collapse
Affiliation(s)
- Shaakir Hasan
- Division of Radiation Oncology, Allegheny Health Network, Pittsburgh, Pennsylvania, USA
| | - Michael J Gigliotti
- Division of Radiation Oncology, Allegheny Health Network, Pittsburgh, Pennsylvania, USA
| | - Melvin Deutsch
- Department of Radiation Oncology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - Stacey L Reed
- Department of Pathology, Allegheny Health Network, Pittsburgh, Pennsylvania, USA
| | - Rodney E Wegner
- Division of Radiation Oncology, Allegheny Health Network, Pittsburgh, Pennsylvania, USA
| |
Collapse
|
16
|
Sideris K, Deutsch M, Giambuzzi I, Lange R, Bleiziffer S. TAVI in Patients with Large Aortic Annulus: First Clinical Experience with a New Self-Expandable Prosthesis. Thorac Cardiovasc Surg 2018. [DOI: 10.1055/s-0038-1628118] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- K. Sideris
- Department of Cardiovascular Surgery, German Heart Center Munich, Munich, Germany
| | - M. Deutsch
- Department of Cardiovascular Surgery, German Heart Center Munich, Munich, Germany
| | - I. Giambuzzi
- Department of Cardiovascular Surgery, German Heart Center Munich, Munich, Germany
| | - R. Lange
- Department of Cardiovascular Surgery, German Heart Center Munich, Munich, Germany
| | - S. Bleiziffer
- Department of Cardiovascular Surgery, German Heart Center Munich, Munich, Germany
| |
Collapse
|
17
|
Blokh D, Zurgil N, Stambler I, Afrimzon E, Shafran Y, Korech E, Sandbank J, Deutsch M. An Information-theoretical Model for Breast Cancer Detection. Methods Inf Med 2018. [DOI: 10.3414/me0440] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Summary
Objectives:
Formal diagnostic modeling is an important line of modern biological and medical research. The construction of a formal diagnostic model consists of two stages: first, the estimation of correlation between model parameters and the disease under consideration; and second, the construction of a diagnostic decision rule using these correlation estimates. A serious drawback of current diagnostic models is the absence of a unified mathematical methodological approach to implementing these two stages. The absence of aunified approach makesthe theoretical/biomedical substantiation of diagnostic rules difficult and reduces the efficacyofactual diagnostic model application.
Methods:
The present study constructs a formal model for breast cancer detection. The diagnostic model is based on information theory. Normalized mutual information is chosen as the measure of relevance between parameters and the patterns studied. The “nearest neighbor” rule is utilized for diagnosis, while the distance between elements is the weighted Hamming distance. The model concomitantly employs cellular fluorescence polarization as the quantitative input parameter and cell receptor expression as qualitative parameters.
Results:
Twenty-four healthy individuals and 34 patients (not including the subjects analyzed for the model construction) were tested by the model. Twenty-three healthy subjects and 34 patients were correctly diagnosed.
Conclusions:
The proposed diagnostic model is an open one,i.e.it can accommodate new additional parameters, which may increase its effectiveness.
Collapse
|
18
|
Erlebach M, Ruge H, Deutsch M, Eschenbach L, Wottke M, Lange R, Bleiziffer S. Influence of Predilatation on Stroke, Pacemaker Rate and Paravalvular Leak after Implantation of a Next Generation Self-expandable Transcatheter Aortic Valve Prosthesis. Thorac Cardiovasc Surg 2018. [DOI: 10.1055/s-0038-1627860] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- M. Erlebach
- Department of Cardiac Surgery, German Heart Centre Munich, Munich, Germany
| | - H. Ruge
- Department of Cardiac Surgery, German Heart Centre Munich, Munich, Germany
| | - M. Deutsch
- Department of Cardiac Surgery, German Heart Centre Munich, Munich, Germany
| | - L. Eschenbach
- Department of Cardiac Surgery, German Heart Centre Munich, Munich, Germany
| | - M. Wottke
- Department of Cardiac Surgery, German Heart Centre Munich, Munich, Germany
| | - R. Lange
- Department of Cardiac Surgery, German Heart Centre Munich, Munich, Germany
| | - S. Bleiziffer
- Department of Cardiac Surgery, German Heart Centre Munich, Munich, Germany
| |
Collapse
|
19
|
Voss S, Deutsch M, Schechtl J, Mrad A, Erlebach M, Lange R, Bleiziffer S. Cerebral Embolic Protection during TAVR - Is it Appropriate for Routine Use? Thorac Cardiovasc Surg 2018. [DOI: 10.1055/s-0038-1627861] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- S. Voss
- Department of Cardiovascular Surgery, Clinic at the Technical University Munich, German Heart Center Munich, München, Germany
| | - M. Deutsch
- Department of Cardiovascular Surgery, Clinic at the Technical University Munich, German Heart Center Munich, München, Germany
| | - J. Schechtl
- Department of Cardiovascular Surgery, Clinic at the Technical University Munich, German Heart Center Munich, München, Germany
| | - Agua Mrad
- Department of Cardiovascular Surgery, Clinic at the Technical University Munich, German Heart Center Munich, München, Germany
| | - M. Erlebach
- Department of Cardiovascular Surgery, Clinic at the Technical University Munich, German Heart Center Munich, München, Germany
| | - R. Lange
- Department of Cardiovascular Surgery, Clinic at the Technical University Munich, German Heart Center Munich, München, Germany
| | - S. Bleiziffer
- Department of Cardiovascular Surgery, Clinic at the Technical University Munich, German Heart Center Munich, München, Germany
| |
Collapse
|
20
|
Eschenbach L, Deutsch M, Erlebach M, Günzinger R, Ruge H, Wozniczek O, Lange R, Bleiziffer S. Transcatheter Mitral Valve-in-Valve Implantation versus Conventional Redo Mitral Valve Surgery. Thorac Cardiovasc Surg 2018. [DOI: 10.1055/s-0038-1627923] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- L. Eschenbach
- Department of Cardiac Surgery, German Heart Center Munich, Munich, Germany
| | - M. Deutsch
- Department of Cardiac Surgery, German Heart Center Munich, Munich, Germany
| | - M. Erlebach
- Department of Cardiac Surgery, German Heart Center Munich, Munich, Germany
| | - R. Günzinger
- Department of Cardiac Surgery, German Heart Center Munich, Munich, Germany
| | - H. Ruge
- Department of Cardiac Surgery, German Heart Center Munich, Munich, Germany
| | - O. Wozniczek
- Department of Cardiac Surgery, German Heart Center Munich, Munich, Germany
| | - R. Lange
- Department of Cardiac Surgery, German Heart Center Munich, Munich, Germany
| | - S. Bleiziffer
- Department of Cardiac Surgery, German Heart Center Munich, Munich, Germany
| |
Collapse
|
21
|
Lahm H, Jia M, Dreßen M, Puluca N, Beck N, Cleuziou J, Doppler S, Deutsch M, Lichtner P, Eckstein G, Lange R, Meitinger T, Müller-Myhsok B, Krane M. GWAS Analysis Reveals Previously Unknown Genomic Variants Associated with Different Subgroups of Congenital Heart Disease. Thorac Cardiovasc Surg 2018. [DOI: 10.1055/s-0038-1628044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- H. Lahm
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - M. Jia
- Max-Planck Institute of Psychiatry, Munich, Germany
| | - M. Dreßen
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - N. Puluca
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - N. Beck
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - J. Cleuziou
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - S. Doppler
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - M. Deutsch
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - P. Lichtner
- Helmholtz-Center Munich, Institute of Human Genetics, Neuherberg, Germany
| | - G. Eckstein
- Helmholtz-Center Munich, Institute of Human Genetics, Neuherberg, Germany
| | - R. Lange
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - T. Meitinger
- Helmholtz-Center Munich, Institute of Human Genetics, Neuherberg, Germany
| | | | - M. Krane
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| |
Collapse
|
22
|
Dreßen M, Northoff B, Laue S, Neb I, Zhang Z, Gödel A, Doppler S, Deutsch M, Lahm H, Teupser D, Moretti A, Laugwitz KL, Holdt L, Lange R, Krane M. Identification of Differentially Regulated Pathways in Cardiac Development and Cardiac Gene Expression during In Vitro Cardiac Differentiation of HLHS-derived Human Induced Pluripotent Stem Cells using Transcriptome Analysis. Thorac Cardiovasc Surg 2018. [DOI: 10.1055/s-0038-1628043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- M. Dreßen
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - B. Northoff
- Institute for Laboratory Medicine, University Hospital, Ludwig-Maximilian University Munich, Munich, Germany
| | - S. Laue
- First Department of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
| | - I. Neb
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - Z. Zhang
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - A. Gödel
- First Department of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
| | - S. Doppler
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - M. Deutsch
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - H. Lahm
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - D. Teupser
- Institute for Laboratory Medicine, University Hospital, Ludwig-Maximilian University Munich, Munich, Germany
| | - A. Moretti
- First Department of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
| | - K.-L. Laugwitz
- First Department of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
| | - L. Holdt
- Institute for Laboratory Medicine, University Hospital, Ludwig-Maximilian University Munich, Munich, Germany
| | - R. Lange
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - M. Krane
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| |
Collapse
|
23
|
Krane M, Doll S, Dreßen M, Geyer P, Itzhak D, Braun C, Doppler S, Meyer F, Deutsch M, Lahm H, Lange R, Mann M. Region and Cell-type Specific Proteomic Map of the Human Heart. Thorac Cardiovasc Surg 2018. [DOI: 10.1055/s-0038-1628040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- M. Krane
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - S. Doll
- Proteomics and Signal Transduction, Max-Planck Institute of Biochemistry, Martinsried, Germany
| | - M. Dreßen
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - P. Geyer
- Proteomics and Signal Transduction, Max-Planck Institute of Biochemistry, Martinsried, Germany
| | - D. Itzhak
- Proteomics and Signal Transduction, Max-Planck Institute of Biochemistry, Martinsried, Germany
| | - C. Braun
- Department of Forensic Medicine, Ludwig Maximilian University Munich, Munich, Germany
| | - S. Doppler
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - F. Meyer
- Proteomics and Signal Transduction, Max-Planck Institute of Biochemistry, Martinsried, Germany
| | - M. Deutsch
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - H. Lahm
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - R. Lange
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - M. Mann
- Proteomics and Signal Transduction, Max-Planck Institute of Biochemistry, Martinsried, Germany
| |
Collapse
|
24
|
Ling DC, Bell D, Wollman M, Cheong SK, Deutsch M, Vargo JA. WITHDRAWN: Enhanced Skin Reaction with Palliative Thoracic Radiotherapy and Sorafenib. Pract Radiat Oncol 2017. [DOI: 10.1016/j.prro.2017.06.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
25
|
Soltys KA, Setoyama K, Tafaleng EN, Soto Gutiérrez A, Fong J, Fukumitsu K, Nishikawa T, Nagaya M, Sada R, Haberman K, Gramignoli R, Dorko K, Tahan V, Dreyzin A, Baskin K, Crowley JJ, Quader MA, Deutsch M, Ashokkumar C, Shneider BL, Squires RH, Ranganathan S, Reyes-Mugica M, Dobrowolski SF, Mazariegos G, Elango R, Stolz DB, Strom SC, Vockley G, Roy-Chowdhury J, Cascalho M, Guha C, Sindhi R, Platt JL, Fox IJ. Host conditioning and rejection monitoring in hepatocyte transplantation in humans. J Hepatol 2017; 66:987-1000. [PMID: 28027971 PMCID: PMC5395353 DOI: 10.1016/j.jhep.2016.12.017] [Citation(s) in RCA: 75] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/13/2016] [Revised: 12/12/2016] [Accepted: 12/15/2016] [Indexed: 12/14/2022]
Abstract
BACKGROUND & AIMS Hepatocyte transplantation partially corrects genetic disorders and has been associated anecdotally with reversal of acute liver failure. Monitoring for graft function and rejection has been difficult, and has contributed to limited graft survival. Here we aimed to use preparative liver-directed radiation therapy, and continuous monitoring for possible rejection in an attempt to overcome these limitations. METHODS Preparative hepatic irradiation was examined in non-human primates as a strategy to improve engraftment of donor hepatocytes, and was then applied in human subjects. T cell immune monitoring was also examined in human subjects to assess adequacy of immunosuppression. RESULTS Porcine hepatocyte transplants engrafted and expanded to comprise up to 15% of irradiated segments in immunosuppressed monkeys preconditioned with 10Gy liver-directed irradiation. Two patients with urea cycle deficiencies had early graft loss following hepatocyte transplantation; retrospective immune monitoring suggested the need for additional immunosuppression. Preparative radiation, anti-lymphocyte induction, and frequent immune monitoring were instituted for hepatocyte transplantation in a 27year old female with classical phenylketonuria. Post-transplant liver biopsies demonstrated multiple small clusters of transplanted cells, multiple mitoses, and Ki67+ hepatocytes. Mean peripheral blood phenylalanine (PHE) level fell from pre-transplant levels of 1343±48μM (normal 30-119μM) to 854±25μM (treatment goal ≤360μM) after transplant (36% decrease; p<0.0001), despite transplantation of only half the target number of donor hepatocytes. PHE levels remained below 900μM during supervised follow-up, but graft loss occurred after follow-up became inconsistent. CONCLUSIONS Radiation preconditioning and serial rejection risk assessment may produce better engraftment and long-term survival of transplanted hepatocytes. Hepatocyte xenografts engraft for a period of months in non-human primates and may provide effective therapy for patients with acute liver failure. LAY SUMMARY Hepatocyte transplantation can potentially be used to treat genetic liver disorders but its application in clinical practice has been impeded by inefficient hepatocyte engraftment and the inability to monitor rejection of transplanted liver cells. In this study, we first show in non-human primates that pretreatment of the host liver with radiation improves the engraftment of transplanted liver cells. We then used this knowledge in a series of clinical hepatocyte transplants in patients with genetic liver disorders to show that radiation pretreatment and rejection risk monitoring are safe and, if optimized, could improve engraftment and long-term survival of transplanted hepatocytes in patients.
Collapse
Affiliation(s)
- Kyle A Soltys
- Thomas E. Starzl Transplant Institute, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, United States
| | - Kentaro Setoyama
- Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
| | - Edgar N Tafaleng
- Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
| | - Alejandro Soto Gutiérrez
- Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States; McGowan Institute for Regenerative Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
| | - Jason Fong
- Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
| | - Ken Fukumitsu
- Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
| | - Taichiro Nishikawa
- Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
| | - Masaki Nagaya
- Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
| | - Rachel Sada
- Thomas E. Starzl Transplant Institute, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, United States
| | - Kimberly Haberman
- Thomas E. Starzl Transplant Institute, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, United States
| | - Roberto Gramignoli
- Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm, Sweden
| | - Kenneth Dorko
- Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
| | - Veysel Tahan
- Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
| | - Alexandra Dreyzin
- Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
| | - Kevin Baskin
- Division of Vascular and Interventional Radiology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, United States
| | - John J Crowley
- Division of Vascular and Interventional Radiology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, United States
| | - Mubina A Quader
- Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
| | - Melvin Deutsch
- Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
| | - Chethan Ashokkumar
- Thomas E. Starzl Transplant Institute, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, United States
| | - Benjamin L Shneider
- Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, United States
| | - Robert H Squires
- Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, United States
| | - Sarangarajan Ranganathan
- Department of Pathology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, United States
| | - Miguel Reyes-Mugica
- Department of Pathology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, United States
| | - Steven F Dobrowolski
- Department of Pathology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, United States
| | - George Mazariegos
- Thomas E. Starzl Transplant Institute, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, United States
| | - Rajavel Elango
- Department of Pediatrics, University of British Columbia and Child & Family Research Institute, BC Children's Hospital, Vancouver, Canada
| | - Donna B Stolz
- McGowan Institute for Regenerative Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States; Department of Cell Biology and Physiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
| | - Stephen C Strom
- Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm, Sweden
| | - Gerard Vockley
- Departments of Pediatrics and Human Genetics, University of Pittsburgh School of Medicine and Department of Medical Genetics, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, United States
| | - Jayanta Roy-Chowdhury
- Departments of Medicine and Genetics, Albert Einstein College of Medicine, Bronx, NY, United States; Marion Bessin Liver Research Center, Albert Einstein College of Medicine, Bronx, NY, United States
| | - Marilia Cascalho
- Departments of Surgery and Microbiology and Immunology, University of Michigan, Ann Arbor, MI, United States
| | - Chandan Guha
- Department of Radiation Oncology, Albert Einstein College of Medicine, Bronx, NY, United States
| | - Rakesh Sindhi
- Thomas E. Starzl Transplant Institute, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, United States
| | - Jeffrey L Platt
- Departments of Surgery and Microbiology and Immunology, University of Michigan, Ann Arbor, MI, United States
| | - Ira J Fox
- Thomas E. Starzl Transplant Institute, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, United States; Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States; McGowan Institute for Regenerative Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.
| |
Collapse
|
26
|
Fukuto M, Ocko BM, Bonthuis DJ, Netz RR, Steinrück HG, Pontoni D, Kuzmenko I, Haddad J, Deutsch M. Nanoscale Structure of the Oil-Water Interface. Phys Rev Lett 2016; 117:256102. [PMID: 28036213 DOI: 10.1103/physrevlett.117.256102] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/29/2016] [Indexed: 06/06/2023]
Abstract
X-ray reflectivity (XR) and atomistic molecular dynamics (MD) simulations, carried out to determine the structure of the oil-water interface, provide new insight into the simplest liquid-liquid interface. For several oils (hexane, dodecane, and hexadecane) the XR shows very good agreement with a monotonic interface-normal electron density profile (EDP) broadened only by capillary waves. Similar agreement is also found for an EDP including a sub-Å thick electron depletion layer separating the oil and the water. The XR and MD derived depletions are much smaller than reported for the interface between solid-supported hydrophobic monolayers and water.
Collapse
Affiliation(s)
- M Fukuto
- Condensed Matter Physics and Materials Sciences Department and NSLS II, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - B M Ocko
- Condensed Matter Physics and Materials Sciences Department and NSLS II, Brookhaven National Laboratory, Upton, New York 11973, USA
| | - D J Bonthuis
- Rudolf Peierls Centre for Theoretical Physics, Oxford University, 1 Keble Road, Oxford OX1 3NP, United Kingdom
| | - R R Netz
- Department of Physics, Free University Berlin, D-14195 Berlin, Germany
| | - H-G Steinrück
- Stanford Synchrotron Radiation Lightsource, SLAC National Accelerator Laboratory, Menlo Park, California 94025, USA
| | - D Pontoni
- ESRF-The European Synchrotron, 71 Avenue des Martyrs, 38000 Grenoble, France
| | - I Kuzmenko
- Advanced Photon Source, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - J Haddad
- Physics Department and Institute of Nanotechnology, Bar-Ilan University, Ramat-Gan 52900, Israel
| | - M Deutsch
- Physics Department and Institute of Nanotechnology, Bar-Ilan University, Ramat-Gan 52900, Israel
| |
Collapse
|
27
|
Gkamprela E, Papadimitropoulos V, Papadopoulos N, Deutsch M. Multifocal splenic abscesses in immunocompetent adult due to cat-scratch disease. Hippokratia 2016; 20:306-308. [PMID: 29416305 PMCID: PMC5788231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
BACKGROUND Cat-scratch disease is caused by Bartonella henselae and transmitted to humans via the cats. Patients usually present with cutaneous lesions, regional lymphadenopathy and a brief period of fever. CASE REPORT We report a rare case of an isolated splenic cat-scratch disease in an immunocompetent 27-year-old woman who presented with prolonged fever and multifocal splenic lesions. The patient was treated successfully with a long course of antibiotics. CONCLUSION Isolated splenic lesions and fever is a rare manifestation of the cat-scratch disease. There is need of high suspicion index by the physicians to diagnose the disease promptly without invasive methods. Hippokratia 2016, 20(4): 306-308.
Collapse
Affiliation(s)
- E Gkamprela
- ¹Second Department of Internal Medicine, "Hippokration" General Hospital of Athens, National and Kapodistrian University of Athens, Athens, Greece
| | - V Papadimitropoulos
- ¹Second Department of Internal Medicine, "Hippokration" General Hospital of Athens, National and Kapodistrian University of Athens, Athens, Greece
| | - N Papadopoulos
- ²First Department of Internal Medicine, 417 Army Share Fund Hospital of Athens, Athens, Greece
| | - M Deutsch
- ¹Second Department of Internal Medicine, "Hippokration" General Hospital of Athens, National and Kapodistrian University of Athens, Athens, Greece
| |
Collapse
|
28
|
Katsagoni C, Alexopoulou A, Deutsch M, Papadopoulos N, Papageorgiou M, loannidou P, Papagianni E, Fragopoulou E, Papatheodoridis G, Kontogianni M. SUN-P119: Improvement of Metabolic Syndrome after Intervention Based on Mediterranean Diet in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): A Randomised-Controlled Clinical Trial. Clin Nutr 2016. [DOI: 10.1016/s0261-5614(16)30462-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
29
|
Slasky BS, Sashin D, Horton JA, Sternglass EJ, Bron KM, Deutsch M, Herron JM, Kennedy WH, Boyer JW, Girdany BR, Simpson RW, Hoy RJ, Feist JH. Digital Radiography of the Chest by Self-Scanning Linear Diode Arrays. Acta Radiol 2016. [DOI: 10.1177/028418518702800418] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Diode array digital radiography DADR is a method of radiographic imaging that combines the advantages of computer technology with self-scanning linear diode arrays. These digital images are superior to those obtained by film in recording and displaying information in the lightest and the darkest areas of the film, resulting in a balanced image of the entire thorax without compromising detail, and at reduced radiation dose. This is a direct result of the wide dynamic range, high contrast sensitivity, fiber optic coupling, small diode size, short exposure time, and rejection of scattered x-rays of the system coupled with digital post-processing enhancement of the image displayed at 1024×1024 pixels.
Collapse
|
30
|
Afrimzon E, Botchkina G, Zurgil N, Shafran Y, Sobolev M, Moshkov S, Ravid-Hermesh O, Ojima I, Deutsch M. Hydrogel microstructure live-cell array for multiplexed analyses of cancer stem cells, tumor heterogeneity and differential drug response at single-element resolution. Lab Chip 2016; 16:1047-1062. [PMID: 26907542 DOI: 10.1039/c6lc00014b] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Specific phenotypic subpopulations of cancer stem cells (CSCs) are responsible for tumor development, production of heterogeneous differentiated tumor mass, metastasis, and resistance to therapies. The development of therapeutic approaches based on targeting rare CSCs has been limited partially due to the lack of appropriate experimental models and measurement approaches. The current study presents new tools and methodologies based on a hydrogel microstructure array (HMA) for identification and multiplex analyses of CSCs. Low-melt agarose integrated with type I collagen, a major component of the extracellular matrix (ECM), was used to form a solid hydrogel array with natural non-adhesive characteristics and high optical quality. The array contained thousands of individual pyramidal shaped, nanoliter-volume micro-chambers (MCs), allowing concomitant generation and measurement of large populations of free-floating CSC spheroids from single cells, each in an individual micro-chamber (MC). The optical live cell platform, based on an imaging plate patterned with HMA, was validated using CSC-enriched prostate and colon cancer cell lines. The HMA methodology and quantitative image analysis at single-element resolution clearly demonstrates several levels of tumor cell heterogeneity, including morphological and phenotypic variability, differences in proliferation capacity and in drug response. Moreover, the system facilitates real-time examination of single stem cell (SC) fate, as well as drug-induced alteration in expression of stemness markers. The technology may be applicable in personalized cancer treatment, including multiplex ex vivo analysis of heterogeneous patient-derived tumor specimens, precise detection and characterization of potentially dangerous cell phenotypes, and for representative evaluation of drug sensitivity of CSCs and other types of tumor cells.
Collapse
Affiliation(s)
- E Afrimzon
- Physics Department, The Biophysical Interdisciplinary Schottenstein Center for the Research and Technology of the Cellome, Bar Ilan University, Bldg 214, 5290002, Ramat Gan, Israel.
| | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Capitani F, Gatto S, Postorino P, Palumbo O, Trequattrini F, Deutsch M, Brubach JB, Roy P, Paolone A. The Complex Dance of the Two Conformers of Bis(trifluoromethanesulfonyl)imide as a Function of Pressure and Temperature. J Phys Chem B 2016; 120:1312-8. [DOI: 10.1021/acs.jpcb.5b12537] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- F. Capitani
- Dipartimento di
Fisica, Sapienza Università di Roma, Piazzale A. Moro 5, 00185 Roma, Italy
- Synchrotron SOLEIL, 91192 Gif Sur Yvette, France
| | - S. Gatto
- CNR-ISC, U.O.S. La Sapienza, Piazzale A. Moro 5, 00185 Roma, Italy
| | - P. Postorino
- Dipartimento di
Fisica, Sapienza Università di Roma, Piazzale A. Moro 5, 00185 Roma, Italy
| | - O. Palumbo
- CNR-ISC, U.O.S. La Sapienza, Piazzale A. Moro 5, 00185 Roma, Italy
| | - F. Trequattrini
- Dipartimento di
Fisica, Sapienza Università di Roma, Piazzale A. Moro 5, 00185 Roma, Italy
- CNR-ISC, U.O.S. La Sapienza, Piazzale A. Moro 5, 00185 Roma, Italy
| | - M. Deutsch
- Synchrotron SOLEIL, 91192 Gif Sur Yvette, France
| | | | - P. Roy
- Synchrotron SOLEIL, 91192 Gif Sur Yvette, France
| | - A. Paolone
- CNR-ISC, U.O.S. La Sapienza, Piazzale A. Moro 5, 00185 Roma, Italy
| |
Collapse
|
32
|
Buryk MA, Picarsic JL, Creary SE, Shaw PH, Simons JP, Deutsch M, Monaco SE, Nikiforov YE, Witchel SF. Identification of Unique, Heterozygous Germline Mutation, STK11 (p.F354L), in a Child with an Encapsulated Follicular Variant of Papillary Thyroid Carcinoma within Six Months of Completing Treatment for Neuroblastoma. Pediatr Dev Pathol 2015; 18:318-23. [PMID: 25751324 DOI: 10.2350/15-01-1597-cr.1] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Papillary thyroid carcinoma (PTC) is rare in children, although it is a known secondary malignancy after treatment for neuroblastoma (NB). The interval between NB treatment completion and PTC is usually more than 5 years. A 4-year-old, female patient with a high risk adrenal NB was found to have a 2.9-cm, right thyroid nodule on surveillance chest computed tomography (CT) 6 months after completion of her NB treatment (induction chemotherapy, tumor resection, autologous stem cell transplantation, external beam radiation to the abdominal tumor site, immunotherapy, and retinoic acid). Posttreatment surveillance included iodine-123-metaiodobenzylguanidine scans and CT scans. Fine-needle aspiration of the thyroid nodule diagnosed a follicular neoplasm, which was negative for BRAF, NRAS, KRAS, HRAS, PAX8/PPARg, and RET/PTC mutations, without evidence of metastatic NB. Nodule histology demonstrated an encapsulated follicular variant of PTC (FVPTC). Next-generation sequence analysis for a 46 cancer-gene profile was performed on both tumors with subsequent peripheral blood DNA testing. A heterozygous missense mutation in STK11 (F354L) was identified in both the NB and FVPTC. This mutation was also detected in peripheral blood mononuclear cells. Two additional heterozygous somatic missense mutations of uncertain significance were identified: KDR/VEGF receptor 2 (Q472H) on chromosome 4 and MET (N375S) on chromosome 7. To our knowledge, this is the shortest reported duration from completion of NB treatment to detection of thyroid cancer. The association of the STK11 gene with Peutz-Jeghers syndrome, lung adenocarcinomas, and medullary thyroid cancer leads to a possible association between this genetic variant and our patient's tumors.
Collapse
Affiliation(s)
- Melissa A Buryk
- 1 Division of Endocrinology, Department of Pediatrics, Children's Hospital of Pittsburgh, UPMC, 4401 Penn Ave, Pittsburgh, PA, USA
| | - Jennifer L Picarsic
- 2 Division of Pediatric Pathology, Department of Pathology, University of Pittsburgh School of Medicine, 4401 Penn Ave, Pittsburgh, PA, USA
| | - Susan E Creary
- 3 Division of Hematology and Oncology, Department of Pediatrics, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH, USA
| | - Peter H Shaw
- 4 Division of Pediatric Hematology/Oncology and Bone Marrow Transplantation, Department of Pediatrics, Children's Hospital of Pittsburgh, UPMC, 4401 Penn Ave, Pittsburgh, PA, USA
| | - Jeffrey P Simons
- 5 Division of Pediatric Otolaryngology, University of Pittsburgh School of Medicine, 4401 Penn Ave, Pittsburgh, PA, USA
| | - Melvin Deutsch
- 6 Department of Radiation Oncology, Children's Hospital of Pittsburgh, UPMC, 4401 Penn Ave, Pittsburgh, PA, USA
| | - Sara E Monaco
- 7 Department of Pathology, University of Pittsburgh School of Medicine, 5150 Centre Ave, Pittsburgh, PA, USA
| | - Yuri E Nikiforov
- 8 Department of Pathology, University of Pittsburgh School of Medicine, 3477 Euler Way, Pittsburgh, PA, USA
| | - Selma Feldman Witchel
- 1 Division of Endocrinology, Department of Pediatrics, Children's Hospital of Pittsburgh, UPMC, 4401 Penn Ave, Pittsburgh, PA, USA
| |
Collapse
|
33
|
Naftel RP, Pollack IF, Zuccoli G, Deutsch M, Jakacki RI. Pseudoprogression of low-grade gliomas after radiotherapy. Pediatr Blood Cancer 2015; 62:35-9. [PMID: 25213668 DOI: 10.1002/pbc.25179] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/23/2014] [Accepted: 06/20/2014] [Indexed: 11/07/2022]
Abstract
BACKGROUND Increasing mass effect following radiation therapy (RT) in patients with low-grade gliomas (LGGs) can be mistaken for tumor progression and/or malignant degeneration. Distinguishing pseudoprogression (PP) from true progression is crucial, with vastly different treatment approaches and prognoses. PROCEDURE Patients treated with RT for LGGs through the Children's Hospital of Pittsburgh Neuro-Oncology Program are considered to have PP and managed conservatively if they develop increased mass effect within 3 years of RT. Pre-RT tumor area was compared to the maximum tumor size following RT and the size on the last follow-up scan by a central reviewer. RESULTS Twenty-four children, median age 13 years, received external beam RT for LGG between March 2000 and August 2011. Thirteen patients (54.2%) developed an increase in tumor size compared to baseline beginning at a median of 6 months after RT and lasting for a median of 2.1 years (range 6.5 months to 5.1 years). Maximum tumor enlargement occurred at a median of 8 months after RT, with a range (5 months to 4.2 years). In all 13 cases, the tumor eventually decreased in size without additional anti-tumor therapy. Two patients (8.3%) developed true tumor progression. With a median follow-up of 4.9 years (range 1.0-12.4 years), all patients are alive. CONCLUSIONS Pseudoprogression occurred in more than half of the children with LGG following RT, typically beginning within 8 months and often running a very protracted course. Late presentations can also occur.
Collapse
Affiliation(s)
- Robert P Naftel
- Department of Neurosurgery, Children's Hospital of Pittsburgh, Neurosurgery/Faculty Pavilion, Pittsburgh, Pennsylvania
| | | | | | | | | |
Collapse
|
34
|
Bell EH, Pugh S, Gilbert M, Mehta M, Klimowicz A, Magliocco A, Bredel M, Robe P, Grosu A, Stupp R, Curran W, Corn B, Brown P, Glass J, Souhami L, Jeffrey Lee R, Brachman D, Deutsch M, Won M, Chakravarti A. BI-12 * RTOG 0525 RECURSIVE PARTITIONING ANALYSIS BASED ON CLINICAL AND PROTEIN BIOMARKER PARAMETERS. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou239.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
35
|
Zhou R, Scheurer M, Vera-Bolanos E, Gilbert M, Bondy M, Sulman E, Hilsenbeck S, Wendland M, Brachman D, Roof K, Komaki R, Deutsch M, Andrews D, Anderson B, Lee RJ, Pugh S, Armstrong T. CN-21 * RISK MODELING FOR TEMOZOLOMIDE (TMZ)-MYELOTOXICITY IN PATIENTS WITH GLIOBLASTOMA TREATED ON RTOG 0825. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou243.21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Steinrück HG, Magerl A, Deutsch M, Ocko BM. Pseudorotational epitaxy of self-assembled octadecyltrichlorosilane monolayers on sapphire (0001). Phys Rev Lett 2014; 113:156101. [PMID: 25375723 DOI: 10.1103/physrevlett.113.156101] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/17/2014] [Indexed: 06/04/2023]
Abstract
The structure of octadecyltrichlorosilane self-assembled monolayers (SAMs) on sapphire (0001) was studied by Å-resolution surface-specific x-ray scattering methods. The monolayer was found to consist of three sublayers where the outermost layer corresponds to vertically oriented, closely packed alkyl tails. Laterally, the monolayer is hexagonally packed and exhibits pseudorotational epitaxy to the sapphire, manifested by a broad scattering peak at zero relative azimuthal rotation, with long powderlike tails. The lattice mismatch of ∼ 1%-3% to the sapphire's and the different length scale introduced by the lateral Si-O-Si bonding prohibit positional epitaxy. However, the substrate induces an intriguing increase in the crystalline coherence length of the SAM's powderlike crystallites when rotationally aligned with the sapphire's lattice. The increase correlates well with the rotational dependence of the separation of corresponding substrate-monolayer lattice sites.
Collapse
Affiliation(s)
- H-G Steinrück
- Crystallography and Structural Physics, University of Erlangen-Nürnberg, 91058 Erlangen, Germany
| | - A Magerl
- Crystallography and Structural Physics, University of Erlangen-Nürnberg, 91058 Erlangen, Germany
| | - M Deutsch
- Physics Department and Institute of Nanotechnology, Bar-Ilan University, Ramat-Gan 52900, Israel
| | - B M Ocko
- Condensed Matter Physics and Materials Science Department, Brookhaven National Lab, Upton, New York 11973, USA
| |
Collapse
|
37
|
Koskinas JS, Deutsch M, Adamidi S, Skondra M, Tampaki M, Alexopoulou A, Manolakopoulos S, Pectasides D. The role of tenofovir in preventing and treating hepatitis B virus (HBV) reactivation in immunosuppressed patients. A real life experience from a tertiary center. Eur J Intern Med 2014; 25:768-71. [PMID: 25037900 DOI: 10.1016/j.ejim.2014.06.028] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/15/2014] [Revised: 06/06/2014] [Accepted: 06/30/2014] [Indexed: 12/27/2022]
Abstract
INTRODUCTION/AIM Patients who present HBV reactivation during immunosuppressive treatment are prone to develop life threatening decompensation of the liver function, therefore prophylaxis and treatment are strongly recommended. So far there are no data regarding the role of tenofovir in this context. Therefore, the aim of our study was to describe our "real life" experience with the use of tenofovir (TDF) in patients who underwent immunosuppressive treatment. RESULTS 38 patients with immunosuppression received antiviral treatment with tenofovir (25 patients as prophylaxis and 13 patients as treatment of HBV reactivation). In all 25 patients in whom prophylactic treatment with tenofovir was administered no HBV flare occurred during immunosuppression and the levels of serum HBV-DNA became or remained undetectable during the follow up period (mean follow up 17.2 months, range 6-54). One patient experienced HBsAg seroconversion. In the 13 patients who exhibited HBV reactivation TDF treatment resulted in complete biochemical and virological response within 6 months except two patients with high pretreatment HBV-DNA levels who became HBV-DNA negative at 9 months. No exacerbation of liver disease or liver related death has been observed. One patient who presented with decompensated cirrhosis during HBV reactivation returned into a compensated state after treatment. No side effects of tenofovir have been documented. CONCLUSION Tenofovir seems to be highly effective and safe in the prophylaxis and rescue treatment of HBV reactivation in patients who receive immunosuppression therapy.
Collapse
Affiliation(s)
- J S Koskinas
- Second Department of Internal Medicine, Medical School of Athens University, Hippokration General Hospital, Athens, Greece.
| | - M Deutsch
- Second Department of Internal Medicine, Medical School of Athens University, Hippokration General Hospital, Athens, Greece
| | - S Adamidi
- Second Department of Internal Medicine, Medical School of Athens University, Hippokration General Hospital, Athens, Greece
| | - M Skondra
- Second Department of Internal Medicine, Medical School of Athens University, Hippokration General Hospital, Athens, Greece
| | - M Tampaki
- Second Department of Internal Medicine, Medical School of Athens University, Hippokration General Hospital, Athens, Greece
| | - A Alexopoulou
- Second Department of Internal Medicine, Medical School of Athens University, Hippokration General Hospital, Athens, Greece
| | - S Manolakopoulos
- Second Department of Internal Medicine, Medical School of Athens University, Hippokration General Hospital, Athens, Greece
| | - D Pectasides
- Second Department of Internal Medicine, Medical School of Athens University, Hippokration General Hospital, Athens, Greece
| |
Collapse
|
38
|
Suntharalingam M, Winter K, Ilson D, Dicker A, Kachnic L, Konski A, Chakravarthy B, Anker C, Thakrar H, Horiba N, Kavadi V, Deutsch M, Raben A, Roof M, Videtic G, Pollack J, Safran H, Crane C. The Initial Report of Local Control on RTOG 0436: A Phase 3 Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Treated Without Surgery. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.06.022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
39
|
Zurgil N, Ravid-Hermesh O, Shafran Y, Howitz S, Afrimzon E, Sobolev M, He J, Shinar E, Goldman-Levi R, Deutsch M. Donut-shaped chambers for analysis of biochemical processes at the cellular and subcellular levels. Lab Chip 2014; 14:2226-2239. [PMID: 24829933 DOI: 10.1039/c3lc51426a] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
In order to study cell-cell variation with respect to enzymatic activity, individual live cell analysis should be complemented by measurement of single cell content in a biomimetic environment on a cellular scale arrangement. This is a challenging endeavor due to the small volume of a single cell, the low number of target molecules and cell motility. Micro-arrayed donut-shaped chambers (DSCs) of femtoliter (fL), picoliter (pL), and nanoliter (nL) volumes have been developed and produced for the analysis of biochemical reaction at the molecular, cellular and multicellular levels, respectively. DSCs are micro-arrayed, miniature vessels, in which each chamber acts as an individual isolated reaction compartment. Individual live cells can settle in the pL and nL DSCs, share the same space and be monitored under the microscope in a noninvasive, time-resolved manner. Following cell lysis and chamber sealing, invasive kinetic measurement based on cell content is achieved for the same individual cells. The fL chambers are used for the analysis of the same enzyme reaction at the molecular level. The various DSCs were used in this proof-of-principle work to analyze the reaction of intracellular esterase in both primary and cell line immune cell populations. These unique DSC arrays are easy to manufacture and offer an inexpensive and simple operating system for biochemical reaction measurement of numerous single cells used in various practical applications.
Collapse
Affiliation(s)
- N Zurgil
- The Biophysical Interdisciplinary Schottenstein Center for the Research and Technology of the Cellome, Physics Department, Bar Ilan University, 52900, Ramat Gan, Israel.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Papatheodoridis GV, Manolakopoulos S, Margariti A, Papageorgiou MV, Kranidioti H, Katoglou A, Kontos G, Adamidi S, Kafiri G, Deutsch M, Pectasides D. The usefulness of transient elastography in the assessment of patients with HBeAg-negative chronic hepatitis B virus infection. J Viral Hepat 2014; 21:517-24. [PMID: 24750382 DOI: 10.1111/jvh.12176] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/21/2013] [Accepted: 08/15/2013] [Indexed: 12/09/2022]
Abstract
Histological severity is often mandatory for the management of HBeAg-negative chronic HBV patients. We evaluated the performance of transient elastography (TE) in this setting. We included 357 untreated HBeAg-negative patients with ≥ 1 reliable liver stiffness measurement (LSM-kPa) by TE: 182 inactive carriers with HBV-DNA < 2000 (n = 139) or 2000-19 999 IU/mL (n = 43) and 175 patients with chronic hepatitis B (CHB). In carriers, HBV-DNA > 2000 and/or LSM > 6.5 were considered as biopsy indications. LSMs did not differ between carriers with low and high viremia, but were lower in carriers than in patients with CHB (5.8 ± 1.7 vs 9.0 ± 5.6, P < 0.001) offering moderate differentiation between these two groups (AUROC: 0.705). LSMs did not change significantly in carriers after 16 (12-24) months. In carriers with a liver biopsy, Ishak's staging scores were similar between cased with low and high viremia but higher in cases with LSM > 6.5 than ≤ 6.5 kPa. Moderate fibrosis (stages: 2-3) was detected in 0/10 carriers with only HBV-DNA > 2000 IU/mL, 2/10 (20%) carriers with only LSM > 6.5 and 5/10 (50%) carriers with both HBV-DNA > 2000 and LSM > 6.5 (P = 0.009). In patients with CHB, LSMs correlated significantly with grading and staging scores and offered excellent accuracy for ≥ moderate, ≥ severe fibrosis or cirrhosis (AUROC ≥ 0.919-0.950). TE can be helpful for the noninvasive assessment of HBeAg-negative chronic HBV patients. In conclusion, LSMs offer excellent accuracy for fibrosis severity in HBeAg-negative patients with CHB and can identify carriers with high risk of moderate fibrosis, which may be present in up to 35% of carriers with LSM > 6.5 kPa and 50% of carriers with LSM > 6.5 kPa and HBV-DNA > 2000 IU/mL.
Collapse
Affiliation(s)
- G V Papatheodoridis
- 2nd Department of Internal Medicine, Athens University Medical School, 'Hippokration' General Hospital of Athens, Athens, Greece
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Ilson D, Winter K, Suntharalingham M, Dicker A, Kachnic L, Konski A, Chakravarthy A, Anker C, Thakrar H, Horiba N, Kavadi V, Giguere J, Deutsch M, Raben A, Roof K, Videtic G, Pollock J, Safran H, Crane C. Rtog 0436: A Phase III Trial of Cisplatin, Paclitaxel and Radiation with or Without Cetuximab in the Nonoperative Treatment of Esophageal Cancer. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu193.5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Eaton BR, Pugh SL, Bradley JD, Kavadi V, Narayan S, Nedzi LA, Robinson CG, Deutsch M, Koprowski CD, Johnson DW, Meng J, Curran WJ. The effect of institutional clinical trial enrollment volume on survival of patients with stage III non-small cell lung cancer treated with chemoradiation: A report of the Radiation Therapy Oncology Group (RTOG) 0617. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.7551] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Bree Ruppert Eaton
- Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
| | - Stephanie L. Pugh
- Statistical Center, Radiation Therapy Oncology Group, Philadelphia, PA
| | - Jeffrey D Bradley
- Washington University School of Medicine in St. Louis, St. Louis, MO
| | | | - Samir Narayan
- Michigan Cancer Research Consortium CCOP, Ann Arbor, MI
| | | | | | | | | | | | - JoAnne Meng
- Ottawa Regional Cancer Centre, Ottowa, ON, Canada
| | - Walter J. Curran
- Radiation Therapy Oncology Group; Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
| |
Collapse
|
43
|
Ilson DH, Moughan J, Suntharalingam M, Dicker A, Kachnic LA, Konski AA, Chakravarthy B, Anker C, Thakrar HV, Horiba N, Kavadi V, Deutsch M, Raben A, Roof KS, Suh JH, Pollock J, Safran H, Crane CH. RTOG 0436: A phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for patients with esophageal cancer treated without surgery. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.4007] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Jennifer Moughan
- Statistical Center, Radiation Therapy Oncology Group, Philadelphia, PA
| | | | - Adam Dicker
- Department of Radiation Oncology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | | | - Andre A. Konski
- Karmanos Cancer Institute, Wayne State University, Detroit, MI
| | | | | | | | | | | | | | - Adam Raben
- Helen F. Graham Cancer Center, Wilmington, DE
| | | | | | | | - Howard Safran
- Brown University Oncology Research Group, Providence, RI
| | | |
Collapse
|
44
|
Suntharalingam M, Winter K, Ilson DH, Dicker A, Kachnic LA, Konski AA, Chakravarthy B, Gaffney DK, Thakrar HV, Horiba MN, Deutsch M, Kavadi V, Raben A, Roof KS, Videtic GMM, Pollock J, Safran H, Crane CH. The initial report of RTOG 0436: A phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for patients with esophageal cancer treated without surgery. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.3_suppl.lba6] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
LBA6 Background: RTOG 0436 is a randomized Ph III trial designed to evaluate the benefit of cetuximab added to the concurrent chemoradiation for patients undergoing non-operative management of esophageal carcinoma. Methods: Pts with biopsy-proven squamous cell or adenocarcinoma of the esophagus (T1N1M0; T2-4 AnyN M0; Any T/N M1a) were randomized to weekly concurrent cisplatin (50 mg/m2), paclitaxel (25 mg/m2), and daily radiation 50.4 Gy/1.8 Gy fractions ± weekly cetuximab (400 mg/m2 day 1 then weekly 250 mg/m2). Patients were stratified by histology, tumor size (< 5 cm vs > 5cm), and the status of celiac lymph nodal involvement. Overall survival (OS) was the primary endpoint, with a planned accrual of 420 pts to detect an increase in 2-year OS from 41% to 53%; 80% power and 1-sided 0.025 alpha. An interim analysis of cCR was planned for the first 150 of each histology. Results: The study accrued 344 pts from 2008-2013 and 328 were eligible. Based on interim analyses, the study stopped accruing adeno pts in 5/2012 and SCC pts in 1/2013. Pts were well matched for pretreatment characteristics: 80% with T3/4 disease, 66% N1, and 19% with celiac nodal involvement. Incidence of grade 3/4/5 treatment (tx) related AEs was 45%, 22%, 4% in Arm 1 (cetuximab) and 49%, 17%, 1% in Arm 2 (no cetuximab). A cCR rate of 56% was observed in Arm 1 vs 59% in Arm 2 (p=0.72). No differences were seen in cCR between tx arms for either histology. The 12 and 24 mo OS rates for cCR pts were 79% and 58% vs 53% and 30% for those with residual disease (p<0.0001). Median follow-up for all pts is 15.4 mos. The 12 and 24 mo OS (95% CI) for Arm 1 is 64% (56%, 71%) and 44% (36%, 52%) vs 65% (57%, 72%) and 42% (34%, 50%) for Arm 2 (p=0.70). Adeno pts (n=203) had a 12 and 24 mo OS of 65% and 43% for Arm 1 vs 64% and 41% for Arm 2 (p=0.37). The 12 and 24 mo OS for the 125 SCC pts was 62% and 46% for Arm 1 vs 67% and 43% for Arm 2 (p=0.97). Conclusions: The addition of cetuximab to concurrent chemoradiation did not improve OS. There were no differences in cCR rates by tx arm. These Ph III results point to little benefit for current EGFR targeted agents in the tx of esophageal cancer. Supported by RTOG CA21661 and CCOP CA3742 NCI grants and Bristol Myers Squibb. Clinical trial information: NCT00655876.
Collapse
Affiliation(s)
- Mohan Suntharalingam
- University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD
| | - Kathryn Winter
- Radiation Therapy Oncology Group-Statistical Center, Philadelphia, PA
| | | | - Adam Dicker
- Department of Radiation Oncology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | | | - Andre A. Konski
- Karmanos Cancer Institute/Wayne State University, Detroit, MI
| | | | - David K. Gaffney
- Huntsman Cancer Hospital at University of Utah, Salt Lake City, UT
| | - Harish V. Thakrar
- John H. Stronger, Jr. Hospital of Cook County Minority-Based Community Clinical Oncology Program, Chicago, IL
| | | | | | | | - Adam Raben
- Helen F. Graham Cancer Center, Wilmington, DE
| | | | | | | | - Howard Safran
- Brown University Oncology Research Group, Providence, RI
| | | |
Collapse
|
45
|
Striki A, Manolakopoulos S, Deutsch M, Mela M, Kalafateli M, Schini M, Anagnostou O, Triantos C, Andreadis I, Ketikoglou I, Papatheodoridis G, Pectasides D. Cirrhosis but not neutropenia is associated with the development of infection in patients with chronic hepatitis C undergoing treatment with pegylated interferon-alpha and ribavirin. J Viral Hepat 2013; 21:624-32. [PMID: 24224747 DOI: 10.1111/jvh.12197] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/11/2013] [Accepted: 09/21/2013] [Indexed: 12/18/2022]
Abstract
Peginterferon-alpha (PegIFNa) frequently causes neutropenia, mainly due to bone marrow suppression. The aim of this study was to explore factors that are associated with infections during antiviral treatment. We analysed data from 275 chronic hepatitis C (CHC) patients with compensated liver disease who underwent 318 courses of PegIFNa and ribavirin. Neutropenia was defined as neutrophils <1000 cells/μL. Mean leucocytes count significantly decreased from baseline to treatment nadir (7081 ± 2182 vs 3293 ± 1331 cells/μL, P < 0.001), while neutropenia was observed in 32% during treatment. Thirty-one infections were observed. The incidence rate for infection was assessed at 1.46 infections per 100 person-months of therapy. The hazard rate for infection did not correlate with the neutrophils' nadir or the decrease in white blood cells. In multivariate Cox's regression analysis, cirrhosis was the only factor that was significantly associated with the occurrence of infection. Our data show that the development of bacterial infections during treatment with PegIFNa and ribavirin in patients with compensated CHC is not associated with reduction or the nadir of white cells or neutrophil counts. Baseline cirrhosis is the only factor related with infection during treatment. The common practice of dose adjustment or discontinuation of interferon should be revised; careful assessment of liver damage before therapy and close monitoring during therapy are essential in all patients receiving interferon-based regimes, to minimize the detrimental consequences of infections.
Collapse
Affiliation(s)
- A Striki
- 2nd Academic Department of Internal Medicine, Hippokratio Hospital of Athens, Athens, Greece
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Badiu CC, Deutsch M, Sideris C, Krane M, Hettich I, Voss B, Mazzitelli D, Lange R. 224 * AORTIC ROOT REPLACEMENT: COMPARISON OF CLINICAL OUTCOME BETWEEN DIFFERENT SURGICAL TECHNIQUES. Interact Cardiovasc Thorac Surg 2013. [DOI: 10.1093/icvts/ivt372.224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
47
|
Beriwal S, Shinde A, Rajagopalan MS, Kannan N, Heron DE, Deutsch M. Recommendations for post-mastectomy radiation therapy after neo-adjuvant chemotherapy: an International Survey of Radiation Oncologists. Breast J 2013; 19:683-4. [PMID: 24118536 DOI: 10.1111/tbj.12193] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Affiliation(s)
- Sushil Beriwal
- Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
| | | | | | | | | | | |
Collapse
|
48
|
Deutsch M, Claiser N, Gillon B, Gillet JM, Lecomte C, Luneau D, Souhassou M. Experimental spin-resolved electron densities: results of a joint refinement of XRD and PND data. Acta Crystallogr A 2013. [DOI: 10.1107/s0108767313099212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
49
|
Stern C, Trapp EM, Mautner E, Deutsch M, Lang U, Cervar-Zivkovic M. Schwere Präeklampsie und ihr Einfluss auf die mütterliche Lebensqualität. Geburtshilfe Frauenheilkd 2013. [DOI: 10.1055/s-0033-1347726] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
50
|
Deutsch M, Panageas K, Lassman A, DeAngelis L. Predicting Failure To Taper Steroids in Newly Diagnosed Glioblastoma (P04.184). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.p04.184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|